# Biocartis NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biocartis

- Industry: Biotechnology
- Headquarters: Mechelen, Belgium
- Website: www.biocartis.com
- Total disclosed funding: $377M
- Latest round: Series F (Jul 29, 2014)
- Investors on record: 17

## About

Biocartis NV, located in Belgium, specializes in molecular diagnostics, offering innovative testing solutions that streamline personalized medicine through rapid and accurate results.Founded in 2007 and headquartered in Mechelen, Belgium, Biocartis NV focuses on molecular testing solutions in the healthcare sector. The company raised EUR 40.000 mn through a Recapitalisation round in 2015, marking an important milestone in its funding journey. CEO Roger Moody has been instrumental in guiding the company's strategic direction since its inception.Biocartis develops advanced biotechnology solutions, primarily through its Idylla™ platform, a fully automated, real-time PCR-based system delivering molecular biomarker results within three hours. The platform includes various assays, including the POLE-POLD1 Mutation Assay and the MSI Test, catering to oncologists, pathologists, and laboratories globally. Its products are marketed primarily in Europe, North America, and Asia, enhancing the efficiency of molecular diagnostics.In 2023, Biocartis reported a revenue of EUR 55,987,195.6 with an EBITDA of EUR -38,669,071.1, deriving its income from the sale of Idylla™ products and associated assays used in clinical laboratories.Biocartis aims to expand its product offerings with new assays and enhancements to the Idylla™ platform, leveraging insights from recent funding to support these developments. The company also plans to penetrate new markets in Asia and North America by 2025, focusing on increasing access to its molecular diagnostic solutions. In April 2015, the company raised EUR 100 million in an IPO, utilizing those funds to bolster its growth initiatives.

## Funding rounds

- Series F, Jul 29, 2014, $146M — Johnson & Johnson Innovation, PMV, Showa Denko Materials Co., Ltd.
- Series E, Dec 19, 2013, $28M — Wellcome Trust, Johnson & Johnson Innovation, Korys, PMV, Petercam, Debiopharm Group, Valiance, Benaruca, RMM, Philips Health Technology Ventures
- Series D, Dec 12, 2012, $45M — Johnson & Johnson Innovation, Korys, PMV, Debiopharm Group, Valiance, Benaruca, New Rhein Healthcare Investors, RMM, Philips Health Technology Ventures
- Series C, Nov 17, 2011, $98M — Wellcome Trust, Johnson & Johnson Innovation, Korys, PMV, Debiopharm Group, Biovest, Valiance, Benaruca, New Rhein Healthcare Investors, Droia Ventures, Philips Health Technology Ventures
- Series B, Sep 1, 2010, $6.4M — Johnson & Johnson Innovation
- Series B, Apr 8, 2010, $40M — Johnson & Johnson Innovation, Aescap Venture, Debiopharm Group, Biovest, Advent Life Sciences
- Series A, Oct 15, 2009, $15M — KBC Private Equity, Aescap Venture, Biovest, Benaruca, Advent Life Sciences

## Investors

- KBC Private Equity (https://capitalatlas.ai/funds/kbc-private-equity) — Series A
- Aescap Venture (https://capitalatlas.ai/funds/aescap-venture) — Series A, Series B
- Biovest — Series A, Series B, Series C
- Benaruca — Series A, Series C, Series D, Series E
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C, Series D, Series E, Series F
- Debiopharm Group — Series B, Series C, Series D, Series E
- Wellcome Trust — Series C, Series E
- Korys (https://capitalatlas.ai/funds/korys) — Series C, Series D, Series E
- PMV (https://capitalatlas.ai/funds/pmv) — Series C, Series D, Series E, Series F
- Valiance (https://capitalatlas.ai/funds/valiance) — Series C, Series D, Series E
- New Rhein Healthcare Investors (https://capitalatlas.ai/funds/new-rhein-healthcare-investors) — Series C, Series D
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series C
- Philips Health Technology Ventures (https://capitalatlas.ai/funds/philips-health-technology-ventures) — Series C, Series D, Series E
- RMM — Series D, Series E
- Petercam — Series E
- Showa Denko Materials Co., Ltd. — Series F